Literature DB >> 7528855

Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.

P Tosi1, G Visani, E Ottaviani, S Manfori, P L Zinzani, S Tura.   

Abstract

It has been reported that the adenine nucleoside analogue fludarabine is able to increase the phosphorylation and the cytotoxicity of cytosine arabinoside (Ara-C) in different leukemic models, both in vitro and in vivo. In poor prognosis acute myeloid leukemia (AML), the combination of fludarabine with Ara-C and granulocyte colony-stimulating factor (G-CSF) has proven to be a highly effective regimen. In this study we aimed to further investigate the effects of this drug combination. In vitro, on fresh AML cells from ten patients, our results confirm an additive cytotoxic effect displayed by fludarabine + Ara-C, as demonstrated by isobologram analysis of the data. The addition of G-CSF significantly increased the efficacy of the drug combination. These effects appeared to be related to an increased incorporation of [3H]Ara-C into cellular DNA in the presence of fludarabine + G-CSF. Furthermore, the quantitative evaluation of programmed cell death (apoptosis) showed that fludarabine + Ara-C + G-CSF induce apoptosis to a higher degree than either compound alone. This finding suggests that cooperative induction of apoptosis could be the potential mechanism of action of this drug combination.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528855

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Authors:  Inaam Bashir Hassan; Jorgen Kristensen; Khalid Al Qawasmeh; Arif Alam
Journal:  Int J Hematol       Date:  2018-06-27       Impact factor: 2.490

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Effect of granulocyte colony-stimulating factor on chemotherapeutic activity of cytosine arabinoside in acute leukemic cell lines.

Authors:  K E Cha; S Y Yoon; K N Lee
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.

Authors:  Jennifer Davila; Emily Slotkin; Thomas Renaud
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

5.  The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Se Ryeon Lee; Deok Hwan Yang; Jae Sook Ahn; Yeo Kyeoung Kim; Je Jung Lee; Young Jin Choi; Ho Jin Shin; Joo Seop Chung; Yoon Young Cho; Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Hyeoung Joon Kim
Journal:  J Korean Med Sci       Date:  2009-06-15       Impact factor: 2.153

6.  FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.

Authors:  Şebnem Yılmaz Bengoa; Eda Ataseven; Deniz Kızmazoğlu; Fatma Demir Yenigürbüz; Melek Erdem; Hale Ören
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.